FlashRNA® is a cutting-edge mRNA platform providing the highest possible level of safety as a ready-to-inject drug product and offering transformative potential in RNA vaccines as well as a wide range of cell and gene therapy applications. This safe technology promises to be a game-changer, enabling the next generation of medical treatments, particularly in the realm of infectious diseases.

The mRNA vaccine market is experiencing explosive growth, with projections indicating a compound annual growth rate of over 30% through 2030^[1]. This surge is driven by the success of COVID-19 vaccines and the expanding pipeline of mRNA vaccines for various infectious diseases, including influenza, Zika, and respiratory syncytial virus (RSV) ^[2].

FlashRNA^® is poised to play a key role in this rapidly evolving landscape. Its unique technology, inspired by nature’s own mechanisms for RNA transfer, offers unparalleled efficiency in mRNA delivery. This breakthrough could significantly enhance the development of vaccines against a wide array of pathogens, potentially revolutionizing our approach to infectious disease prevention and treatment ^[3].

“Our commitment to innovation and excellence in RNA technology is reflected in the launch of GMP production for FlashRNA^®,” said Christine Duthoit, CSO of Flash BioSolutions. “This milestone is a testament to the hard work and dedication of our development and transfer teams, as well as our operations and quality teams, whose joint efforts have made this achievement possible.”

Anne Deflisque, Business Director, added, “The start of industrial-scale GMP production is a critical step in bringing our groundbreaking solutions to market. With FlashRNA^®, we’re not just participating in the mRNA revolution – we’re helping to lead it. Our technology’s efficiency and versatility position us uniquely to address the growing demand for mRNA-based solutions in infectious disease control and beyond.”

Jérôme Bédier, CEO, concluded, “Flash BioSolutions is at the forefront of mRNA technology, and with FlashRNA^®, we are set to make a significant impact on the future of medicine. Our technology’s ability to vehicle RNA with unprecedented efficiency could accelerate the development of vaccines for challenging infectious diseases and improve global health outcomes. We congratulate our entire team for their exceptional work in reaching this pivotal moment.”

The expansion complements Flash BioSolutions’ existing GMP and RUO capacities, enabling the company to deliver 1000+ lentiviral constructions per year. This is in addition to the impressive 11,000 constructions performed over the past 20 years, showcasing the company’s extensive experience and reliability in the field.

The decision to reemerge as Flash BioSolutions® signifies a pivotal juncture in the company’s journey, signifying its unwavering resolve to fortify its foothold in the global pharmaceutical outsourcing arena as an indomitable force.

Dr. Christine Duthoit, Chief Scientific Officer at Flash BioSolutions, highlights the significance of this expansion: “Our RUO lentiviruses play a key role in several promising pharmaceutical developments in gene therapy and cancer immunotherapy. They are essential for CAR and TCR research and the development of therapeutic vaccines. In research, these lentiviruses are invaluable tools for creating stable cell lines and studying gene function. They also aid in developing animal models. Additionally, in regenerative medicine, we are exploring approaches that use RNA vectors for reprogramming  and differentiation purposes .”

Leveraging its strategic location in France, Flash BioSolutions offers unparalleled expertise and a distinct advantage in serving European and North American markets, enhancing responsiveness and significantly reducing delivery times.

“This expansion underscores our ambition to support the exponential growth of gene and cell therapies across Europe and North America” states Jérôme Bédier, CEO of Flash BioSolutions. “Our strategic position in France, combined with our enhanced capabilities, enables us to provide crucial support to clients worldwide, addressing the challenges of a rapidly evolving international market. We are fully prepared to make a transformative contribution to the advancement of regenerative medicine and vaccination on a truly global scale.”